1022919-86-3 Purity
---
If you have any other questions or need other size, please get a quote.
Specification
The molecular formula of lifitegrast is C29H24Cl2N2O7S.
The molecular weight of lifitegrast is 615.5 g/mol.
The IUPAC name of lifitegrast is (2S)-2-[[2-(1-benzofuran-6-carbonyl)-5,7-dichloro-3,4-dihydro-1H-isoquinoline-6-carbonyl]amino]-3-(3-methylsulfonylphenyl)propanoic acid.
The InChI of lifitegrast is InChI=1S/C29H24Cl2N2O7S/c1-41(38,39)20-4-2-3-16(11-20)12-23(29(36)37)32-27(34)25-22(30)13-19-15-33(9-7-21(19)26(25)31)28(35)18-6-5-17-8-10-40-24(17)14-18/h2-6,8,10-11,13-14,23H,7,9,12,15H2,1H3,(H,32,34)(H,36,37)/t23-/m0/s1.
The InChIKey of lifitegrast is JFOZKMSJYSPYLN-QHCPKHFHSA-N.
The canonical SMILES of lifitegrast is CS(=O)(=O)C1=CC=CC(=C1)CC(C(=O)O)NC(=O)C2=C(C=C3CN(CCC3=C2Cl)C(=O)C4=CC5=C(C=C4)C=CO5)Cl.
Lifitegrast is a Lymphocyte Function-Associated Antigen-1 Antagonist.
Lifitegrast was approved by the FDA in July 2016 under the trade name Xiidra for the treatment of keratoconjunctivitis sicca (dry eye syndrome).
Lifitegrast has a role as an anti-inflammatory drug and a lymphocyte function-associated antigen-1 antagonist.
The KEGG ID of lifitegrast is D10374.